SCHEMBL17599360

SCHEMBL17599360

O=C(O)c1cccc(-c2ccc(NS(=O)(=O)c3ccc(Cl)cc3Cl)c3ccccc23)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGA1 P56199 3/20 0.56
WDR5 P61964 1/20 0.51
SERPINE1 P05121 2/20 0.49
SLC16A3 O15427 1/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
SLC40A1 Q9NP59 1/20 0.47
ACLY P53396 2/20 0.47
PTK2B Q14289 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
FABP4 P15090 2/20 0.46
BCL2L1 Q07817 1/20 0.46
MCL1 Q07820 1/20 0.46
FABP5 Q01469 1/20 0.46
PTGES2 Q9H7Z7 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599340 0.92 SLC16A3 (0.58) ITGA1WDR5SERPINE1SLC16A3KMT2A
SCHEMBL17599402 0.90 BRD4 (0.52) ITGA1WDR5KMT2AMEN1ACLY
SCHEMBL17599404 0.88 KMT2A (0.48) WDR5SERPINE1SLC16A3KMT2AMEN1
SCHEMBL17599330 0.87 WDR5 (0.47) ITGA1WDR5KMT2AMEN1ACLY
SCHEMBL17599379 0.86 ACLY (0.54) WDR5SLC16A3KMT2AMEN1ACLY
SCHEMBL17599371 0.85 KMT2A (0.51) WDR5SLC16A3KMT2AMEN1ACLY
SCHEMBL17599403 0.84 WDR5 (0.49) WDR5SLC16A3KMT2AMEN1SLC40A1
SCHEMBL17599353 0.84 ACLY (0.58) SERPINE1KMT2AACLYPTK2BKDM4E
SCHEMBL17599310 0.83 PTK2B (0.53) WDR5KMT2AACLYPTK2BSMN1; SMN2
SCHEMBL17599406 0.82 ACLY (0.58) WDR5SERPINE1KMT2AMEN1ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed